Slingshot Insights | Iova Overview

IOVA Overview

Upcoming Projects (IOVA)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (IOVA)

Discussing the potential of Iovance's TIL therapy, lifileucel, and the results from the Phase 2 study in patients with melanoma presented at the ESMO 2023 conference.
Ticker: IOVA
Executed On: Nov 03, 2023 at 04:00 PM EDT
Discussing therapeutics in development for melanoma including Moderna/Merck's mRNA-4157 cancer vaccine and Iovance Biotherapeutics' TIL therapy, lifileucel.
Tickers: MRNA, IOVA, MRK
Executed On: May 09, 2023 at 10:30 AM EDT
Examining the potential of Iovance's tumor infiltrating lymphocyte (TIL) therapy, lifileucel, in advanced unresectable or metastatic melanoma
Ticker: IOVA
Executed On: Apr 13, 2023 at 03:00 PM EDT

Expired Projects (IOVA)

Analyzing Iovance's lifileucel Compared to Instil Bio’s main candidate, ITIL-168, in Melanoma
Tickers: IOVA, TIL
Execute By: Jun 25, 2021
Comparing results metastatic melanoma in PD-1 progressing patients. IOVA, IDRA, ONCS, REPL, CMPI all have results at this year's SITC in this 2L PD-1 refractory melanoma population. We ask an expert to compare trial designs and results
Tickers: IOVA, IDRA, ONCS, REPL, CMPI
Execute By: Jan 29, 2021
Another View: Understanding the disease, standard of care, current treatment paradigm and the unmet need in treating Melamoma with a focus on IOVA's LN-145
Ticker: IOVA
Execute By: Sep 20, 2018

Upcoming & Overdue Catalysts (IOVA)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (IOVA)

Phase 2 long-term data of Iovance's(IOVA) LN-144 - lifileucel in Refractory metastatic melanoma to be presented at AACR meeting April 10, 2021, 3:30 PM
Ticker: IOVA
Occurred on: Apr 09, 2021

Strategic Initiatives (IOVA)

Don’t see a strategic initiative related to the company you care about? Create your own!